NYSE · Healthcare
Nasus Pharma Ltd (NSRX)
As-reported financials and recent SEC filings for Nasus Pharma Ltd, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.24B
Net income
$-5.9M
Net margin
-0.5%
Diluted EPS
$-0.72
ROE
-211.6%
P/E (TTM)
—
Market cap
$38.9M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2025 | FY2025 |
|---|---|---|---|
| Revenue | $1.24B | — | — |
| Gross profit | — | — | — |
| Operating income | $-4.9M | $-1.1M | $-1.1M |
| Net income | $-5.9M | $-1.5M | $-1.1M |
| Diluted EPS | $-0.72 | $-0.22 | $-0.20 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →6-K2026-06-09
View on EDGAR →S-82026-05-26
View on EDGAR →SCHEDULE 13G2026-05-15
View on EDGAR →42026-04-22
View on EDGAR →SCHEDULE 13G2026-04-07
View on EDGAR →42026-04-01
View on EDGAR →EFFECT2026-03-31
View on EDGAR →Go deeper on NSRX
Search Nasus Pharma Ltd’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.